MedTrace Logo

Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients

NCT05319093 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2025-11-28

No results posted yet for this study

Summary

Multi-center observational study to assess the short-term response of multiple sclerosis (MS) patients initiated on Ozanimod with respect to fatigue. Patterns of brain changes on brain magnetic resonance imaging (MRI) that might modulate the effect of Ozanimod treatment on fatigue will also be assessed.

Conditions

Interventions

DRUG

Ozanimod

Three-months, longitudinal observational period

Sponsors & Collaborators

Principal Investigators

  • Charles RG Guttmann, MD · Brigham and Women's Hospital, Radiology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2024-07-23
Completion
2024-07-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05319093 on ClinicalTrials.gov